2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1489

“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment
Abstract Number: 1152

“Doctor, a Storm Is Coming and My Joints Hurt”: Evaluating Associations between Weather Changes and Arthritis Symptoms
Abstract Number: 2349

“I Was Prepared for the Other Side Effects; I Wasn’t Prepared for This One.”: A Qualitative Study of the Patients’ Experience of Inflammatory Arthritis Due to Immune Checkpoint Inhibitor Therapy for Cancer
Abstract Number: 2787

−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)
Abstract Number: 415

1-Year Outcomes from a Novel Physical Therapist-Administered Physical Activity Intervention after Total Knee Replacement: A Pilot Study
Abstract Number: 145

1,25(OH)2D3 and Dexamethasone Additively Suppress Synovial Fibroblast Activation By CCR6+ T-Helper Memory Cells and Enhance the Effect of Tnfα Blockade
Abstract Number: 2950

10X Genomics-Based Single-Cell RNA-Seq Analysis Identifies a Transcriptional Landscape of Inflammation and Fibrosis in Lupus Nephritis
Abstract Number: 924

10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block
Abstract Number: 833

11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK
Abstract Number: 2720

30-Day Hospital Readmission for Granulomatosis with Polyangiitis: Analysis from National Readmission Database
Abstract Number: 610

4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
Abstract Number: 2086

4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
Abstract Number: 2803

48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase
Abstract Number: 1758

A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2171

A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample

1
2
3
…
202
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].